Enhancing Life Through Psychedelic & Medicinal Mushrooms

Alleviating mental health disorders, and improving lives, through the discovery, development and commercialization of psychedelic and medicinal mushrooms.

NeonMind is dedicated to the improvement of life through engaging the mind to heal the body:

Treating Addiction & Disorders of the Mind

Enhancing the Functions of the Mind and Senses

Healing the Body Through the Mind

We are developing plans for clinical trials to support our research into potentially therapeutic benefits of compounds found in psychedelic mushrooms. We aim to be a leader in the fast-growing functional foods market by offering high-quality mushroom-infused products that support immune, cognitive, memory and other brain functions.

Magical Potential

Psychedelic therapy has been deemed to have potential for treating a variety of mental illnesses, labelled a "breakthrough therapy" for the 100 million people suffering from treatment resistant depression. Studies are underway worldwide to examine psychedelics to treat many illnesses that are mind related.

NeonMind is conducting research and development into therapeutic uses of psychedelics

Global Projected Markets (USD)

Major factors expected to drive the weight related market at a CAGR of 6.9%, are increasing obese population, increasing number of bariatric surgeries, growing adoption of online weight loss and weight management programs, rise in disposable income in developing economies, sedentary lifestyle, and increasing government initiatives for creating awareness among obese population.

Increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth of the market. According to the American Heart Association (AHA), Cardiovascular disease accounted for 1 of every 3 US deaths in 2016. Also, between 2013 and 2016, 121.5 million Americans had some form of cardiovascular disease. Further, cardiovascular disease, as a cause of death in the U.S., is likely to account for more than 23.6 million by 2030.

One hundred million of those diagnosed with major depressive disorder (MDD) are said to suffer from treatment-resistant depression (TRD). This accounts for approximately 33% of MDD cases.The FDA decision to fast track the testing of psilocybin could allow for psychedelic mushrooms to penetrate this market.

Reaching $69.7B in 2019, the diabetes treatment market is anticipated to register a CAGR of over 4.5% during the forecast period (2020 - 2025). This is primarily due to the increasing global diabetes population due to stress, unhealthy diets, and overweight. In China and the United States alone, there are more than 120 and 25 million diabetes patients respectively, and this number is expected to increase significantly through 2025.

Upward trend in sedentary lifestyles, physical inactivity, and unhealthy food habits are the vital factors responsible for the high prevalence of obesity. According to the Institute of Health Metrics and Evaluation, about 30.0% of the global population is either obese or overweight.